Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.
Ashraf GM, Greig NH, Khan TA, Hassan I, Tabrez S, Shakil S, Sheikh IA, Zaidi SK, Akram M, Jabir NR, Firoz CK, Naeem A, Alhazza IM, Damanhouri GA, Kamal MA.
CNS Neurol Disord Drug Targets. 2014;13(7):1280-93.
Similar articles
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
Tabrez S, Jabir NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):395-409. Review.
Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia.
Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baeesa SS, Kamal MA.
Med Chem. 2016;12(3):226-37. Review.
Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modeling and docking study.
Shakil S, Khan R, Tabrez S, Alam Q, Jabir NR, Sulaiman MI, Greig NH, Kamal MA.
CNS Neurol Disord Drug Targets. 2011 Nov;10(7):845-8.
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.
Shakil S, Kamal MA, Tabrez S, Abuzenadah AM, Chaudhary AG, Damanhouri GA.
CNS Neurol Disord Drug Targets. 2012 Mar;11(2):142-7.
Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA, Shakil S, Nawaz MS, Yu QS, Tweedie D, Tan Y, Qu X, Greig NH.
CNS Neurol Disord Drug Targets. 2017;16(7):820-827. doi: 10.2174/1871527316666170207160606.
Human platelet acetylcholinesterase inhibition by cyclophosphamide: a combined experimental and computational approach.
Al-Jafari AA, Shakil S, Reale M, Kamal MA.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):928-35.
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease.
Rizvi SM, Shaikh S, Waseem SM, Shakil S, Abuzenadah AM, Biswas D, Tabrez S, Ashraf GM, Kamal MA.
EXCLI J. 2015 May 19;14:684-96. doi: 10.17179/excli2015-252. eCollection 2015. Review.
Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease.
Jabir NR, Firoz CK, Ashraf GM, Zaidi SK, Shakil S, Kamal MA, Tabrez S.
Curr Vasc Pharmacol. 2017;15(4):365-373. doi: 10.2174/1570161115666170105125034.
An overview on the correlation of neurological disorders with cardiovascular disease.
Firoz CK, Jabir NR, Khan MS, Mahmoud M, Shakil S, Damanhouri GA, Zaidi SK, Tabrez S, Kamal MA.
Saudi J Biol Sci. 2015 Jan;22(1):19-23. doi: 10.1016/j.sjbs.2014.09.003. Epub 2014 Sep 6. Review.
C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome.
Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA.
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):921-7.
Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome.
Jabir NR, Firoz CK, Khan MS, Zaidi SK, Ashraf GM, Shakil S, Kamal MA, Tabrez S.
Curr Drug Metab. 2017;18(1):62-68. doi: 10.2174/1389200217666160810155055.
Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Rizvi SM, Shakil S, Biswas D, Shakil S, Shaikh S, Bagga P, Kamal MA.
CNS Neurol Disord Drug Targets. 2014 Apr;13(3):447-51.
A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications.
Jabir NR, Tabrez S, Firoz CK, Zaidi SK, Baeesa SS, Gan SH, Shakil S, Kamal MA.
Curr Drug Metab. 2015;16(5):336-45. Review.
Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases.
Jabir NR, Siddiqui AN, Firoz CK, Ashraf GM, Zaidi SK, Khan MS, Shakil S, Alama MN, Kamal MA, Tabrez S.
Curr Pharm Des. 2016;22(5):566-71. Review.
Nanotechnology-based approaches in anticancer research.
Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA.
Int J Nanomedicine. 2012;7:4391-408. doi: 10.2147/IJN.S33838. Epub 2012 Aug 9. Review.
Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases.
Ashraf GM, Perveen A, Zaidi SK, Tabrez S, Shakil S, Ahmad A, Haque R, Ahsan J, Kamal MA, Banu N.
Protein Pept Lett. 2015;22(11):954-62. Review.
Estimation of Interleukin-1β Promoter (-31 C/T and -511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients.
Tabrez S, Jabir NR, Firoz CK, Hindawi S, Shakil S, Damanhouri GA, Zaidi SK.
J Cell Biochem. 2017 Sep;118(9):2977-2982. doi: 10.1002/jcb.25958. Epub 2017 Apr 12.
Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase.
Parveen Z, Nawaz MS, Shakil S, Greig NH, Kamal MA.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):463-8.
Linkage of Stress with Neuromuscular Disorders.
Ashraf GM, Ali A, Tabrez S, Zaidi SK, Shakil S, Alam MZ, Rehan M, Aliev G.
CNS Neurol Disord Drug Targets. 2016;15(3):321-8. Review.
Filters: Manage Filters